In conclusion, our research demonstrated that GM-CSF potentially triggered the loss of tumor immune surveillance in ENKTL patients and promoted disease progression, which was associated with STAT5A mutations and JAK2 hyperphosphorylation, and then upregulates the expression of PD-L1. Here, JAK2 is linked to neoplasm.